Welcome to our dedicated page for SBTX news (Ticker: SBTX), a resource for investors and traders seeking the latest updates and insights on SBTX stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SBTX's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SBTX's position in the market.
Silverback Therapeutics, Inc. (Nasdaq: SBTX) has announced that CEO Laura Shawver, Ph.D., will present at several upcoming virtual investor conferences. Key events include the Goldman Sachs West Coast Biotech Bus Tour on February 23, 2021, the SVB Leerink 10th Annual Global Healthcare Conference on February 24, 2021, the Cowen 41st Annual Healthcare Conference on March 3, 2021, and the H.C. Wainwright Global Life Sciences Conference on March 9, 2021. Webcasts and replays of selected presentations will be available on Silverback's website for 30 days.
Silverback Therapeutics, Inc. (Nasdaq: SBTX) has successfully closed its initial public offering of 13,225,000 shares at $21.00 per share, raising approximately $277.7 million in gross proceeds. The offering includes the full exercise of the underwriters' option to purchase additional shares. Shares began trading on December 4, 2020. Goldman Sachs & Co. LLC, SVB Leerink, and Stifel served as joint book-running managers, while H.C. Wainwright & Co. was the lead manager. Registration statements are effective as of December 3, 2020, and copies are available on the SEC's website.
Silverback Therapeutics announced the pricing of its initial public offering (IPO) of 11,500,000 shares at $21.00 each, aiming for gross proceeds of $241.5 million. The shares will list on Nasdaq under the symbol SBTX, starting December 4, 2020, with the offering expected to close on December 8, 2020. A 30-day option for underwriters to purchase an additional 1,725,000 shares at the IPO price has been included. Goldman Sachs, SVB Leerink, and Stifel serve as joint book-running managers for this offering.